Brokerages Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Price Target at $3.75

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has received a consensus recommendation of “Hold” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $3.75.

HOWL has been the topic of several analyst reports. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th.

Insider Buying and Selling at Werewolf Therapeutics

In related news, Director Luke Evnin sold 305,741 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $0.70, for a total value of $214,018.70. Following the transaction, the director owned 1,273,008 shares of the company’s stock, valued at $891,105.60. This represents a 19.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 376,526 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $0.71, for a total value of $267,333.46. Following the completion of the sale, the insider owned 418,813 shares in the company, valued at approximately $297,357.23. This represents a 47.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,197,572 shares of company stock worth $1,380,702 in the last three months. 23.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its stake in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Vanguard Group Inc. increased its stake in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Renaissance Technologies LLC increased its stake in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares during the last quarter. Jane Street Group LLC acquired a new stake in Werewolf Therapeutics during the second quarter worth approximately $409,000. Finally, Citadel Advisors LLC acquired a new stake in Werewolf Therapeutics during the third quarter worth approximately $304,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $0.42 on Thursday. The company has a market cap of $20.53 million, a price-to-earnings ratio of -0.34 and a beta of 0.29. The stock’s 50-day moving average is $0.72 and its two-hundred day moving average is $0.74. Werewolf Therapeutics has a 1-year low of $0.40 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. Equities research analysts anticipate that Werewolf Therapeutics will post -1.29 earnings per share for the current fiscal year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.